Healthcare · NSE: ERIS
Eris Lifesciences
Q2 FY27 earnings highlights, from the results presentation
Q2 FY27 · From the investor presentation
- M.Cap
- ₹18,427Cr
- P/E
- 26.0×
- 1Y return
- −14.24%
- From 52W high
- −23.6%
Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.
Share price
Results Q2 FY27, as filed · consolidated · ₹ Cr
| Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ | |
|---|---|---|---|---|---|
| Revenue | 892 | 792 | +12.6% | 873 | +2.2% |
| EBITDA | 309 | 288 | +7.3% | 296 | +4.4% |
| EBITDA margin | 34.7% | 36.4% | -170 bps | 33.9% | +75 bps |
| One-off items | -36 | — | — | — | — |
| PBTProfit before tax | 157 | 172 | -9.0% | 180 | -12.8% |
| Net profit | 184 | 120 | +52.9% | 142 | +29.0% |
| EPS (₹) | 13.25 | 8.81 | +50.4% | 10.26 | +29.1% |
From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures.
Guidance
Domestic Branded Formulations: DBF EBITDA slightly ahead of guidance in Q2
Slides · p. 5
Domestic Branded Formulations: DBF EBITDA slightly ahead of guidance in Q2
“DBF EBIDTA slightly ahead of guidance in Q2”
Domestic Branded Formulations: Further gross margin gain expected from portfolio out-licensed to Zorvia
Slides · p. 6
Domestic Branded Formulations: Further gross margin gain expected from portfolio out-licensed to Zorvia
“Further gross margin gain expected from the out-licensed portfolio”
In short
- 01Q2 FY27 consolidated revenue grew 12.6% and PAT grew 39.2%.
- 02Q2 EBITDA was Rs 309 cr at a 34.7% margin, up 7.3%.
- 03DBF revenue grew 14.1%; ex-Zorvia DBF growth was 16.5%.
- 04Ex-Zorvia, about 100 bps DBF gross margin improvement is expected going forward.
- 05A Rs ~36 cr receivables write-off was booked; the NCLT merger order gave a Rs 65 cr tax benefit.
- 06Capex cycle is winding down; Swiss Unit III PV batches expected by Apr 27.
- 07Net debt fell by about Rs 111 cr in H1.
Capex
Swiss Parenterals: Swiss new Unit III construction on track; PV batches by Apr 27
Slides · p. 11
Swiss Parenterals: Swiss new Unit III construction on track; PV batches by Apr 27
“• Construction on track; PV batches by Apr 27”
Capex cycle winding down by end of FY27
Slides · p. 14
Capex cycle winding down by end of FY27
“Capex cycle is winding down by end of as % of Revenue 23.3% 20.7% 22.2% 21.2% FY27”
Eris Bionxt, Swiss and Levim investments yet to contribute; returns expected from next year
Slides · p. 14
Eris Bionxt, Swiss and Levim investments yet to contribute; returns expected from next year
“Three major capital investments - Eris EBITDA Margin 34.7% 36.4% 34.3% 36.1% Bionxt, Swiss and Levim - are yet to Depreciation 17 12 36.8% 32 26 21.2% Amortisation 57 57 - 113 113 - contribute; returns expected from next Finance Cost 46 50 -6.3% 93 98 -5.3% year”
Capacity
Bhopal facility commercialized; vials and cartridges in production
Slides · p. 6
Bhopal facility commercialized; vials and cartridges in production
“Bhopal facility commercialized Gain Vials and Cartridges now in production”
Full manufacturing shift to Bhopal expected in second half of next year
Slides · p. 6
Full manufacturing shift to Bhopal expected in second half of next year
“Complete shift expected in the second half of next year”
Swiss Parenterals: Unit III lines planned: PFS, vials, lyophilized and cartridges
Slides · p. 11
Swiss Parenterals: Unit III lines planned: PFS, vials, lyophilized and cartridges
“• Lines planned: PFS, Vials, Lyophilized and Cartridges (incl. Dual Chamber)”
Segments
Domestic Branded Formulations: Ex-Zorvia, Q2 DBF growth is 16.5%
Slides · p. 5
Domestic Branded Formulations: Ex-Zorvia, Q2 DBF growth is 16.5%
“• Ex-Zorvia, Q2 DBF growth is 16.5%”
Ex-Zorvia Eris growth is 17%
Slides · p. 7
Ex-Zorvia Eris growth is 17%
“Ex-Zorvia Eris growth is 17%.”
Diabetes: Diabetes emerged stronger after insulin and semaglutide launches
Slides · p. 8
Diabetes: Diabetes emerged stronger after insulin and semaglutide launches
“Diabetes has emerged stronger after Insulins and Semaglutide launches We also have the strongest pipeline of products going ahead in diabetes”
Swiss Parenterals: Swiss top 10 countries contribute 50%+ of export revenues
Slides · p. 11
Swiss Parenterals: Swiss top 10 countries contribute 50%+ of export revenues
“Base Business Top 10 countries Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 Business intact, steady and protected Contribute 50% + of export revenues”
Domestic Branded Formulations: 86% of portfolio chronic and sub-chronic; top 10 brands 44% of sales
Slides · p. 4
Domestic Branded Formulations: 86% of portfolio chronic and sub-chronic; top 10 brands 44% of sales
“86% portfolio is Chronic and Sub-chronic with Top 10 brands contributing to 44% of Sales”
Demand
Margins and costs
Domestic Branded Formulations: DBF EBITDA margin fell 191 bps in Q2 to 35.7% and 217 bps in H1 to 35.2%
Slides · p. 5
Domestic Branded Formulations: DBF EBITDA margin fell 191 bps in Q2 to 35.7% and 217 bps in H1 to 35.2%
“EBITDA margin: 37.6% → 35.7% -191 bps EBITDA margin: 37.4% → 35.2% -217 bps”
Domestic Branded Formulations: DBF other expenses rose 29.8% in Q2 to Rs 187 cr
Slides · p. 9
Domestic Branded Formulations: DBF other expenses rose 29.8% in Q2 to Rs 187 cr
“Other Expenses 187 144 29.8% 357 287 24.6%”
Debt and working capital
Domestic Branded Formulations: DBF debtor days at 61 in Sep FY27
Slides · p. 9
Domestic Branded Formulations: DBF debtor days at 61 in Sep FY27
“DBF Debtor days at 61 in Sep’ FY27”
H1 operating cash flow was 105% of EBITDA
Slides · p. 13
H1 operating cash flow was 105% of EBITDA
“H1 OCF = 105% of EBIDTA”
Net debt reduced by about Rs 111 cr in H1
Slides · p. 14
Net debt reduced by about Rs 111 cr in H1
“Net Debt reduction of ~111 cr in H1”
Consolidated debtor days at 70 in Sep FY27
Slides · p. 14
Consolidated debtor days at 70 in Sep FY27
“Consol Debtor days at 70 in Sep’ FY27”
Acquisitions and new business
Domestic Branded Formulations: Injectables licensed to Zorvia Healthcare; Eris keeps brands and earns 7% royalty
Slides · p. 5
Domestic Branded Formulations: Injectables licensed to Zorvia Healthcare; Eris keeps brands and earns 7% royalty
“to Zorvia Healthcare; Eris retains brand ownership and earns a 7% royalty”
Domestic Branded Formulations: Brands licensed to Zorvia contribute about Rs 100 cr of sales
Slides · p. 5
Domestic Branded Formulations: Brands licensed to Zorvia contribute about Rs 100 cr of sales
“~₹100 cr of sales”
Diabetes: Nod to conduct Phase 1 and Phase 3 trials for India's first recombinant semaglutide
Slides · p. 8
Diabetes: Nod to conduct Phase 1 and Phase 3 trials for India's first recombinant semaglutide
“• Received the nod to conduct Phase 1 and 37.3% Phase 3 trials for India’s first Recombinant 18.5% Semaglutide”
Diabetes: Three more analogs to enter regulatory pathway from Dec-Mar this financial year
3analogsSlides · p. 8
Diabetes: Three more analogs to enter regulatory pathway from Dec-Mar this financial year
3analogs“• Three more analogs going in the regulatory pathway from Dec-Mar this financial year”
NCLT order received for merger of subsidiaries Aprica, Eris Oaknet and ETL
Slides · p. 9
NCLT order received for merger of subsidiaries Aprica, Eris Oaknet and ETL
“Company has received NCLT order Depreciation 14 10 37.9% 28 20 37.6% for merger between its subsidiaries Amortisation 57 57 - 113 113 - Aprica, Eris Oaknet and ETL.”
One-offs
Domestic Branded Formulations: Receivables write-off of about Rs 36 cr, of at-risk products only
Slides · p. 9
Domestic Branded Formulations: Receivables write-off of about Rs 36 cr, of at-risk products only
“*Receivables write-off of Rs. ~36 cr as % of Revenue 23.1% 20.3% 22.2% 20.3% of at-risk products only”
Positive tax impact of Rs 65 cr due to NCLT order
Slides · p. 9
Positive tax impact of Rs 65 cr due to NCLT order
“has a positive tax impact of Rs. 65 cr Other Income 2 1 - 5 2 - due to the NCLT order”
Risks
Swiss Parenterals: Swiss base business largely uninterrupted; EU CAPA actions underway
Slides · p. 11
Swiss Parenterals: Swiss base business largely uninterrupted; EU CAPA actions underway
“Base business largely uninterrupted; EU CAPA actions underway”
Swiss Parenterals: EU CAPA execution on track; shutdown planned
Slides · p. 11
Swiss Parenterals: EU CAPA execution on track; shutdown planned
“Execution on track; shutdown planned”
Swiss Parenterals: Swiss EU CAPA shutdown planned in Q3; no CDMO pipeline cancellations
Slides · p. 11
Swiss Parenterals: Swiss EU CAPA shutdown planned in Q3; no CDMO pipeline cancellations
“Execution on track; shutdown planned Current opportunities intact; no in Q3 cancellations”
Other
Domestic Branded Formulations: DBF revenue grew 14.1% YoY in Q2 FY27 with 35.7% EBITDA margin
Slides · p. 5
Domestic Branded Formulations: DBF revenue grew 14.1% YoY in Q2 FY27 with 35.7% EBITDA margin
“Revenue grew 14.1% YoY in Q2 FY27 with EBITDA margin of 35.7%”
Q2 consolidated revenue grew 12.6% and PAT grew 39.2%
Slides · p. 13
Q2 consolidated revenue grew 12.6% and PAT grew 39.2%
“Q2 revenue growth of 12.6% with a PAT growth of 39.2%”
Q2 EBITDA Rs 309 cr, 34.7% margin, up 7.3% YoY
Slides · p. 13
Q2 EBITDA Rs 309 cr, 34.7% margin, up 7.3% YoY
“Q2 EBIDTA = Rs. 309 cr. – 34.7% EBIDTA margin and 7.3% growth yoy”
Q2 PAT Rs 187 cr, up 39.2%; adjusted PAT Rs 158 cr, up 17.5%
Slides · p. 13
Q2 PAT Rs 187 cr, up 39.2%; adjusted PAT Rs 158 cr, up 17.5%
“• Q2 PAT = Rs. 187 cr. – up 39.2% yoy; Adjusted PAT of Rs. 158 cr. – up • H1 Effective Tax Rate = 20.4% 17.5% yoy”
H1 effective tax rate 20.4%
Slides · p. 13
H1 effective tax rate 20.4%
“H1 Effective Tax Rate = 20.4%”
Sources
- Investor presentation, Q2 FY27 Filed 26 Oct 2026 · 17 pages
Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

